Abstract 2187
Background
The number of Chinese cancer survivors is increasing due to the trend of an aging population and improved cancer survival. It is urgently required to estimate the health status of cancer survivors and provide scientific evidence for future health care reform. This study aimed to evaluate the general health status of cancer survivors older than 45 years in China.
Methods
We identified cancer survivors (n = 354) and participants without cancer (n = 16,664) in the China Health and Retirement Longitudinal Study (CHARLS). Physical and mental health information collected by questionnaire were compared between cancer survivors and cancer-free controls.
Results
The mean age of cancer survivors was 61.0 years. More cancer survivors were female (68.9% vs. 52.3%, P < 0.001) and lived in a rural region (43.8% vs. 38.4%, P = 0.039) than those without cancer. Cancer survivors and participants without cancer did not show significant differences in age, marital status, education or BMI. The health status of middle-aged and older cancer survivors are shown in the table. Cancer survivors had more concomitant chronic diseases than participants without cancer (2.75 vs. 2.00, P < 0.001). The current health condition reported by cancer survivors themselves was poorer than no cancer group (3.87 vs. 3.38, P < 0.001). The daily activity score was higher in the cancer group (3.53 vs. 2.39, P < 0.001), which indicated that cancer survivors had more difficulties in their daily life than other middle-aged and older participants. There was no statistically significant difference in cognitive function between these two groups even after adjustment (12.61 vs. 12.90, P = 0.612). Cancer survivors had more depressive symptoms than participants without cancer after adjustment (10.07 vs. 8.01, P = 0.003).Table: 1649P
Health status of middle-aged and older cancer survivors and participants without cancer from the CHARLS
Characteristic | Total (N = 17,018) | Cancer survivors (n = 354) | No cancer (n = 16,664) | P value | P value† |
---|---|---|---|---|---|
Number of concomitant chronic diseases, mean ± SD | 2.02 ± 1.70 | 2.75 ± 2.13 | 2.00 ± 1.69 | <0.001 | |
Self-reported health score (1-5), mean ± SD | 3.39 ± 0.38 | 3.87 ± 0.82 | 3.38 ± 0.87 | <0.001 | <0.001 |
Daily activity, mean ± SD | 2.41 ± 3.36 | 3.53 ± 3.85 | 2.39 ± 3.35 | <0.001 | <0.001 |
Cognitive function, mean ± SD | 12.89 ± 5.69 | 12.61 ± 5.60 | 12.90 ± 5.69 | 0.629 | 0.612 |
Depression, mean ± SD | 8.05 ± 6.41 | 10.07 ± 7.06 | 8.01 ± 6.39 | <0.001 | 0.003 |
Adjusted for age, sex, region, and number of concomitant chronic diseases.
Conclusions
The health status of middle-aged and older cancer survivors is poor in China. High-quality and cost-effective supportive care for these individuals is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (No. 61435001) and CAMS Innovation Fund for Medical Sciences (No. 2016-I2M-1-001, No. 2017-I2M-4-003).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2963 - Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib
Presenter: Ira Pekker
Session: Poster Display session 3
Resources:
Abstract
3523 - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3295 - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)
Presenter: Laura Bonanno
Session: Poster Display session 3
Resources:
Abstract
5632 - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform
Presenter: Martin Reijans
Session: Poster Display session 3
Resources:
Abstract
3614 - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy
Presenter: Theresa May
Session: Poster Display session 3
Resources:
Abstract
5664 - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Presenter: Christina Grech
Session: Poster Display session 3
Resources:
Abstract
4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)
Presenter: Panagiotis Apostolou
Session: Poster Display session 3
Resources:
Abstract
5746 - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies
Presenter: Rocio Rosas-Alonso
Session: Poster Display session 3
Resources:
Abstract
5901 - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
2027 - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells
Presenter: Chaeyong Jung
Session: Poster Display session 3
Resources:
Abstract